Vulvovaginal pyoderma gangrenosum secondary to rituximab therapy

Please use this identifier to cite or link to this item: https://mnclhd.intersearch.com.au/mnclhdjspui/handle/123456789/584

Full metadata record

DC Field	Value	Language
dc.contributor.author	Dixit, S.	-
dc.contributor.author	Selva-Nayagam, P.	-
dc.contributor.author	Hamann, I.	-
dc.contributor.author	Fischer, G.	-
dc.date.accessioned	2025-03-27T03:54:58Z	-
dc.date.available	2025-03-27T03:54:58Z	-
dc.date.issued	2015-01	-
dc.identifier.citation	J Low Genit Tract Dis . 2015 Jan;19(1):e6-9. doi: 10.1097/LGT.0000000000000043.	en
dc.identifier.uri	https://mnclhd.intersearch.com.au/mnclhdjspui/handle/123456789/584	-
dc.description.abstract	Rituximab is being used increasingly for the treatment of B-cell malignancies and nonmalignant conditions. Pyoderma gangrenosum is a rare neutrophilic dermatosis, which can be either idiopathic or associated with underlying systemic inflammatory conditions. We present a series of 4 patients who presented with ulcerative pyoderma gangrenosum in the vulvovaginal area after treatment with rituximab.	en
dc.subject	Rituximab	en
dc.subject	Pyoderma Gangrenosum	en
dc.subject	Dermatitis	en
dc.subject	Neoplasms	en
dc.title	Vulvovaginal pyoderma gangrenosum secondary to rituximab therapy	en
dc.type	Article	en
dc.contributor.mnclhdauthor	Hamann, Ian	-
dc.description.pubmeduri	https://pubmed.ncbi.nlm.nih.gov/24769650/	en
dc.identifier.doi	10.1097/LGT.0000000000000043.	en
Appears in Collections:	Oncology / Cancer

Files in This Item:

There are no files associated with this item.

Who's citing